| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7,4 Md € | -5.4% | 7,9 Md € | -11.2% | 8,9 Md € | +23.7% | 7,2 Md € | +45.6% | 4,9 Md € | -24.0% | 6,5 Md € | -4.6% | 6,8 Md € | +44.6% | 4,7 Md € | +5.3% | 4,5 Md € | +8.5% | 4,1 Md € | +29.2% | 3,2 Md € | +7.9% | 2,9 Md € | +5.3% | 2,8 Md € | +6.1% | 2,6 Md € | +0.9% | 2,6 Md € | |
| EBITDA | 4,5 Md € | +15.8% | 3,9 Md € | -21.7% | 4,9 Md € | +34.5% | 3,7 Md € | +79.4% | 2,0 Md € | -36.9% | 3,2 Md € | -4.5% | 3,4 Md € | +59.7% | 2,1 Md € | +47.2% | 1,4 Md € | -5.4% | 1,5 Md € | +60.9% | 946,1 M € | -5.6% | 1,0 Md € | -0.6% | 1,0 Md € | +10.1% | 915,9 M € | -2.0% | 934,3 M € | |
| Operating profit | 2,6 Md € | +16.4% | 2,3 Md € | -29.7% | 3,2 Md € | +66.5% | 1,9 Md € | +345.7% | 431,9 M € | -76.1% | 1,8 Md € | -17.2% | 2,2 Md € | +313.6% | 528,6 M € | +334.6% | -225,3 M € | +51.6% | -465,7 M € | -1633.3% | 30,4 M € | -69.0% | 97,9 M € | -27.6% | 135,3 M € | -15.5% | 160,2 M € | -63.7% | 441,5 M € | |
| Profit/loss | 2,4 Md € | +9.3% | 2,2 Md € | -30.9% | 3,2 Md € | +63.3% | 1,9 Md € | +326.3% | 455,6 M € | -74.4% | 1,8 Md € | -10.6% | 2,0 Md € | +286.5% | 515,2 M € | +296.8% | -261,8 M € | +39.1% | -429,6 M € | -559.2% | 93,6 M € | +495.4% | 15,7 M € | -91.4% | 182,6 M € | -26.8% | 249,4 M € | -56.8% | 577,1 M € | |
| Equity | 10,0 Md € | -24.9% | 13,3 Md € | -24.8% | 17,7 Md € | +21.0% | 14,6 Md € | +12.5% | 13,0 Md € | -26.7% | 17,7 Md € | +0.7% | 17,6 Md € | +12.2% | 15,7 Md € | +2.8% | 15,2 Md € | -2.2% | 15,6 Md € | -3.2% | 16,1 Md € | +18.1% | 13,6 Md € | +0.1% | 13,6 Md € | +1.4% | 13,4 Md € | +1.9% | 13,2 Md € | |
| Total assets | 17,8 Md € | -1.5% | 18,1 Md € | -9.5% | 20,0 Md € | +15.2% | 17,4 Md € | -15.8% | 20,6 Md € | +1.1% | 20,4 Md € | +3.3% | 19,7 Md € | +11.8% | 17,6 Md € | -0.6% | 17,8 Md € | +1.4% | 17,5 Md € | -2.4% | 17,9 Md € | +17.9% | 15,2 Md € | +1.9% | 14,9 Md € | +1.0% | 14,8 Md € | +1.3% | 14,6 Md € | |
| Cash | 21,7 k € | -99.9% | 15,4 M € | -20.2% | 19,2 M € | -11.3% | 21,7 M € | -49.9% | 43,3 M € | +10.3% | 39,2 M € | +66.4% | 23,6 M € | +259.7% | 6,6 M € | +39.8% | 4,7 M € | -60.3% | 11,8 M € | +1166.7% | 931,9 k € | -82.0% | 5,2 M € | -59.1% | 12,6 M € | +209.1% | 4,1 M € | -79.9% | 20,3 M € | |
| Debts | 7,2 Md € | +72.2% | 4,2 Md € | +174.2% | 1,5 Md € | -15.4% | 1,8 Md € | -72.5% | 6,6 Md € | +340.6% | 1,5 Md € | +5.7% | 1,4 Md € | +7.4% | 1,3 Md € | -24.3% | 1,7 Md € | +35.1% | 1,3 Md € | -0.8% | 1,3 Md € | +18.8% | 1,1 Md € | +10.9% | 980,0 M € | +0.8% | 971,8 M € | -19.7% | 1,2 Md € | |
| Staff | 8 371 | 8 681,2 | 8 701,2 | 8 544 | 8 409,2 | 8 753,3 | 8 882,5 | 8 968,3 | 8 643,9 | 8 387,4 | 8 474,2 | 8 212,1 | 7 696,7 | 7 425,7 | 7 251,8 | |||||||||||||||
Public limited company · Rixensart · incorporated on 01/07/1990 · 8 371,0 ETP
Public limited company profitable and well capitalised. Cash position declining (-99.9%).
Solid counterparty for a standard engagement.
GlaxoSmithKline Biologicals is a Public limited company incorporated in 1990. Its main activity is: Fabrication de médicaments. Its registered office is in Rixensart. It employs on average 8 371,0 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette